Nonmydriatic imaging useful in diabetic children

Article

Ophthalmologists may use nonmydriatic retinal imaging to supplement the standard clinical exam to screen diabetic children aged as young as 2 years, according to newly published research.

Ophthalmologists may use nonmydriatic retinal imaging to supplement the standard clinical exam to screen diabetic children aged as young as 2 years, according to newly published research.

US researchers conducted a prospective study of 106 children with type 1 diabetes who were aged 2 to 17 years. The study included an intake form; blood pressure, pulse and oximetry measurements; visual acuity assessment (Simav, Padova) and nonmydriatic colour imaging (CX-1 45° 15.1 megapixel camera, Canon). They assessed images for indications of diabetic retinopathy, and two clinicians graded image quality on a scale of 1 to 5.

Ninety-eight percent of the children underwent imaging. One was found to have nonproliferative diabetic retinopathy, and findings for 2 were incidental.

Sixty-two percent of the children had had an eye exam within the past year, with exams significantly more likely among older children and those who had had type 1 diabetes for more than 5 years.

Investigators graded images as high quality in 178 (86%) eyes, and they said images of some clinical value were obtained in 207 (99.5%) eyes.

The researchers shared their results in the Journal of Pediatric Ophthalmology and Strabismus.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.